Lexaria Bioscience Corp LEXX

Fins on sedar

[lscfa]

Revenue

Product revenues of $17k and licensing usage fees of $16k during period ended February 28, 2022, constitute a significant decline in intermediate product sales and related licensing usage fees. Our primary customer in the B2B product revenue stream has been delayed in chain­store rollouts resulting in overstocked inventory and as such there was no manufacturing & sales of new inventory for this licensee for the quarter ended February 28, 2022.A number of our other licensees are experiencing suspended or curtailed business activities due to the impact of COVID­19 on markets and consumer spending. The abilities of other licensees to generate ongoing sales, thereby increasing usage fees are expected to increase as the effects of the pandemic are eventually diminished and the market acceptance of the products continue to develop. We have continued strong interest in our intermediate products but cannot predict how long the pandemic will affect purchasing decisions of retail customers that ultimately affect the consumer product manufacturers that utilize our intermediate products. Nor can we predict when recovery of the general economy will translate into increasing licensing or usage revenues.

Our licensing revenues consist of IP licensing fees for the transfer of the Technology and usage fees that occur over time. IP licensing fees are due at the signing of definitive agreements for the Technology and can include payments due upon transfer of the Technology and installment payments that are receivable within 12 months.

[WakeUPP]

summary; WE DID A DEAL WITH BEER BEER TURNING OUT TO BE A STOCK PROMO GOING NOWHERE (who woulda thunk??) NOW ARE REVENUE IS ALMOST ZERO OUR STOCK IS HALF SORRY! WE WILL TRY PAYING SOMEONE 5% OF MARKET CAP TO PROMO SOMETHING OUT OF NOTHING